Stage III Skin Cancer
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer (NCT04315701) | University of Southern California | 2020-06-17 |
Track Stage III Skin Cancer automatically
Every clearance here is in the API, with alerts when new ones post.